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SUMMARY 
 
     Pregnane X receptor (PXR) is a major 
transcription factor regulating the inducible 
expression of a variety of transporters and 
drug-metabolizing enzymes including 
cytochrome P450 (CYP) 3A4. We first found 
that the PXR mRNA level was not correlated 
with the PXR protein level in a panel of 25 
human livers, indicating the involvement of 
post-transcriptional regulation. Notably, a 
potential miR-148a recognition element was 
identified in the 3’ untranslated region of human 
PXR mRNA. We investigated whether PXR 
might be regulated by miR-148a. Reporter assay 
revealed that miR-148a could recognize the 
miR-148a recognition element of PXR mRNA. 
The PXR protein level was decreased by the 
overexpression of miR-148a, while it was 
increased by inhibition of miR-148a. The 
miR-148a-dependent decrease of PXR protein 
attenuated the induction CYP3A4 mRNA. 
Furthermore, the translational efficiency of PXR 
(PXR protein/PXR mRNA ratio) was inversely 
correlated with the expression levels of 
miR-148a in a panel of 25 human livers, 
supporting the miR-148a-dependent regulation 
of PXR in human livers. Eventually, the PXR 
protein level was significantly correlated with 
the CYP3A4 mRNA and protein levels. In 
conclusion, we found that miR-148a 
post-transcriptionally regulated human PXR, 
resulting in the modulation of the inducible 
and/or constitutive levels of CYP3A4 in human 
liver. This study will provide new insight into 
the unsolved mechanism of the large 
interindividual variability of CYP3A4 
expression.  
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INTRODUCTION 
 
     A key function of the liver is the metabolism 
and elimination of xenobiotics or endobiotics. 
The expression of genes involved in these 
processes is largely regulated by transcription 
factors belonging to the nuclear receptor family. 
Pregnane X receptor (PXR; alternate names SXR, 
PAR, NR1I2), a member of the nuclear receptor 
family, is a crucial regulator of drug metabolism 
and elimination. It is predominantly expressed in 
liver and small intestine. PXR is activated by a 
broad spectrum of xenobiotics including 
antibiotics, antimycotics, and herbal components 
(1), dimerizes with retinoid X receptor α 
(RXRα) and binds to response elements of target 
genes including cytochrome P450s (CYPs), 
UDP-glucuronosyltransferases (UGTs), 
glutathione S-transferases (GSTs), 
sulfotransferases (SULTs), and various 
transporters such as multidrug resistance 1 
(MDR1) and multidrug resistance associated 
protein 2 (MRP-2) to induce them (2). Thus, 
PXR is recognized as a xenosensor for the 
detoxification of foreign compounds. However, 
it also plays a role as a physiological sensor of 
bile acids to protect the body from toxicity by 
regulating the expression of target genes that 
decreases the synthesis and increases the 
elimination of bile acids (3, 4). 
     One of the best-known genes regulated by 
PXR is CYP3A4, the most abundant P450 in 
human liver that catalyze the metabolism of over 
50% of current prescription drugs (5-7). A large 
interindividual difference (~50-fold) has been 
reported for the CYP3A4 level in the general 
population (8), which cannot be explained by 
genetic polymorphisms (9, 10). The CYP3A4 
expression is largely regulated at the 
transcriptional level by transcriptional factors 
such as CCAAT/enhancer-binding proteins, 
C/EBPα and C/EBPβ  and hepatocyte nuclear 
factors, HNF4α and HNF3γ  as well as 
constitutive androstane receptor (CAR) and PXR 
(11). However, the cause of the large 
interindividual variability in CYP3A4 level is 
poorly understood, and is an urgent issue to be 
solved. The regulation by PXR may, in part, be 
responsible for such variability since PXR is 
activated by endogenous compounds such as 
steroid hormones and bile acids (1, 12), 
     PXR regulates many targets controlling 
pharmacokinetics, but its own regulation is not 
fully understood, with reports showing only that 
human PXR is induced by dexamethasone 
through glucocorticoid receptor (13) or by 
clofibrate through peroxisome 
proliferators-activated receptor α (14). 
Employing an on-line search using the miRBase 
Target database (15, 
http://microrna.sanger.ac.uk/), we found some 
potential recognition sites for microRNAs 
(miRNAs) in the 3’ untranslated region (UTR) of 
the human PXR. 
     miRNAs are a recently discovered family of 
short non-coding RNA whose final product is an 
approximately 22 nucleotide functional RNA 
molecule (16). They play important roles in the 
regulation of target genes by binding to 
complementary regions of transcripts to repress 
  4 
their translation or regulate degradation. At 
present, more than 400 miRNAs have been 
identified in humans and miRNAs are predicted 
to control about 30% of the genes within the 
human genome (17, 18). The roles of miRNAs 
have received attention especially in the cancer 
field, but hardly yet in the field of 
pharmacokinetics. In the present study, we 
investigated whether human PXR might be 
post-transcriptionally regulated by miRNA and 





     Chemicals and reagents - Rifampicin was 
obtained from Wako Pure Chemicals (Osaka, 
Japan). The pGL3-promoter vector, pGL4.74-TK 
plasmid, Tfx-20 reagent and dual-luciferase 
reporter assay system were purchased from 
Promega (Madison, WI). Lipofectamine 2000, 
Lipofectamine RNAiMAX were from Invitrogen 
(Carlsbad, CA). Pre-miR miRNA Precursors for 
miR-148a and for the negative control were from 
Ambion (Austin, TX). Locked nucleic acid 
(LNA) modified antisense oligonucleotides 
(AsOs) for miR-148a (5’- 
ACAAAGTTCTGTAGTGCACTGA-3’, LNA is 
indicated by underline) and for the negative 
control 
(5’-AGACUAGCGGUAUCUUAAACC-3’) 
were commercially synthesized at Greiner 
Bio-One (Tokyo, Japan). All primers and 
oligonucleotides were commercially synthesized 
at Hokkaido System Sciences (Sapporo, Japan). 
Goat anti-human PXR polyclonal antibodies 
(N-16), rabbit anti-human RXRα polyclonal 
antibodies (D-20), and goat anti-human HNF4α 
polyclonal antibodies (S-20) were from Santa 
Cruz Biotechnology (Santa Cruz, CA). Rabbit 
anti-CYP3A4 polyclonal antibodies were from 
BD Gentest (Worburn, MA) and rabbit 
anti-human CAR polyclonal antibodies were 
from CHEMICON (Temecula, CA). Rabbit 
anti-human GAPDH polyclonal antibodies were 
from IMGENEX (San Diego, CA). Alexa Fluor 
680 donkey anti-goat IgG was from Invitrogen. 
IRDye 680 goat anti-rabbit IgG was from 
LI-COR Biosciences (Lincoln, NE). All other 
chemicals and solvents were of the highest grade 
commercially available. 
 
     Human livers and cell culture conditions - 
Human liver samples from 25 donors were 
obtained from Human and Animal Bridging 
(HAB) Research Organization (Chiba, Japan). 
The human hepatocellular carcinoma cell lines 
HepG2 and HuH7 were obtained from Riken 
Gene Bank (Tsukuba, Japan), and HLE was from 
Japanese Collection of Research Bioresources 
(Tokyo, Japan). The human colon carcinoma cell 
lines LS180 and Caco-2, the human embryonic 
kidney cell line HEK293, and the human breast 
adenocarcinoma cell line MCF-7 were obtained 
from American Type Culture Collection 
(Rockville, MD). HepG2, HuH7, and HLE cells 
were cultured in Dulbecco’s modified Eagle’s 
medium (DMEM) (Nissui Pharmaceutical, 
Tokyo, Japan) supplemented with 10% fetal 
bovine serum (FBS) (Invitrogen). LS180, Caco-2, 
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and MCF-7 cells were cultured in DMEM 
supplemented with 0.1 mM non-essential amino 
acid (Invitrogen) and 10% FBS. Differentiated 
Caco-2 (Caco-2/D) cells were obtained by 
culture for three weeks post-confluence. 
HEK293 cells were cultured in DMEM 
supplemented with 4.5 g/L glucose, 10 mM 
HEPES, and 10% FBS. These cells were 
maintained at 37°C under an atmosphere of 5% 
CO2-95% air.  
 
     Real-time RT-PCR for PXR and CYP3A4 - 
Total RNA was isolated from 25 human liver 
samples using ISOGEN (Nippon Gene, Tokyo, 
Japan) according to the manufacturer’s protocol. 
The cDNAs were synthesized from total RNA 
using ReverTra Ace (Toyobo, Osaka, Japan). 
The forward and reverse primers for CYP3A4 
were 5’-CCAAGCTATGCTCTTCACCG-3’ and 
5’-TCAGGCTCCACTTACGGTGC-3’, 
respectively. The forward and reverse primers 
for human PXR were 5’- 
TGCGAGATCACCCGGAAGAC -3’ and 5’- 
ATGGGAGAAGGTAGTGTCAAAGG -3’, 
respectively. The real-time PCR was performed 
using the Smart Cycler (Cepheid, Sunnyvale, 
CA) with Smart Cycler software (Ver. 1.2b) as 
follows: after an initial denaturation at 95°C for 
30 s, the amplification was performed by 
denaturation at 95°C for 6 s, annealing and 
extension at 68°C for 20 s for 40 cycles. The 
mRNA levels were normalized with GAPDH 
mRNA determined by real-time RT-PCR as 
described previously (19). 
 
     SDS-PAGE and Western blot analyses of PXR 
and CYP3A4 - Whole cell lysates were prepared 
from 25 human liver samples by homogenization 
with lysis buffer (50 mM Tris-HCl (pH 8.0), 150 
mM NaCl, 1 mM EDTA, 1% NP-40) containing 
protease inhibitors [0.5 mM APMSF, 2 µg/mL 
aprotinin, 2 µg/mL leupeptin]. The protein 
concentrations were determined using Bradford 
protein assay reagent (Bio-Rad, Hercules, CA) 
with γ-globulin as a standard. The whole cell 
lysates (10-50 µg) were separated with 7.5% 
SDS-polyacrylamide gel electrophoresis and 
transferred to Immobilon-P transfer membrane 
(Millipore, Bedford, MA). The membranes were 
probed with goat anti-human PXR, rabbit 
anti-human CYP3A4, goat anti-human HNF4α, 
rabbit anti-human CAR, or rabbit anti-human 
GAPDH antibodies and the corresponding 
fluorescent dye-conjugated second antibody, and 
the band densities were quantified with Odyssey 
Infrared Imaging system (LI-COR Biosciences). 
Nuclear extracts (10 µg) from the HepG2 and 
LS-180 cells were also used to determine the 
PXR protein level. 
 
     Real-time RT-PCR for mature miR-148a - For 
the quantification of mature miR-148a, 
polyadenylation and reverse transcription were 
performed using the NCode miRNA First-Strand 
cDNA Synthesis Kit (Invitrogen) according to 
the manufacturer’s protocol. The forward primer 
for miR-148a was 5’- 
TCAGTGCACTACAGAACTTTGT -3’, and the 
reverse primer was the supplemented universal 
qPCR primer. The PCR analyses were performed 
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as follows: after an initial denaturation at 95°C 
for 30 s, the amplification was performed by 
denaturation at 95°C for 10 s, annealing and 
extension at 64°C for 10 s for 40 cycles. The 
mature miR-148a level was normalized with U6 
snRNA determined by real-time RT-PCR as 
described previously (20). 
 
     Construction of reporter plasmids - To 
construct luciferase reporter plasmids, various 
target fragments were inserted into the Xba I site 
downstream of the luciferase gene in the 
pGL3-promoter vector. The sequence from 3362 
to 3383 in the human PXR mRNA (5’- 
ACAGACTCTTACGTGGAGAGTGCACTGA 
-3’) was termed miR-148a recognition element 
(PXRMRE148). The fragment containing three 





ACTGACCTGTAT -3’, PXRMRE148 is 
underlined) was cloned into the pGL3-promoter 
vector (pGL3p/3xPXRMRE). The 
complementary sequence of three copies of the 
PXRMRE148 was also cloned into the 
pGL3-promoter plasmid 
(pGL3p/3xPXRMRE-Rev). A fragment 
containing the perfect matching sequence with 
the mature miR-148a, 5’- 
CTAGACAAAGTTCTGTAGTGCACTGAT -3’ 
(the matching sequence of miR-148a is 
underlined) was cloned into the pGL3-promoter 
vector (pGL3p/c-148a). The nucleotide 
sequences of the constructed plasmids were 
confirmed by DNA sequencing analyses.  
 
     Luciferase assay - Various luciferase reporter 
plasmids (pGL3p) were transiently transfected 
with pGL4.74-TK plasmid into HEK293 or 
HepG2 cells. Briefly, the day before transfection, 
the cells were seeded into 24-well plates. After 
24 h, 70 ng of pGL3p plasmid, 30 ng of 
pGL4.74-TK plasmid and 4 pmol of the 
precursors for miR-148a or control were 
transfected into HEK293 cells using 
Lipofectamine 2000. For HepG2 cells, 80 ng of 
pGL3p plasmid, 20 ng of pGL4.74-TK plasmid 
and 10 pmol of the AsOs for miR-148a or 
control were transfected using Tfx-20 reagent. 
After incubation for 48 h, the cells were 
resuspended in passive lysis buffer, and then the 
luciferase activity was measured with a 
luminometer (Wallac, Turku, Finland) using the 
dual-luciferase reporter assay system.  
 
     Transfection of precursor or antisense for 
miR-148a into HepG2 and LS-180 cells and 
isolation of nuclear extract and total RNA - To 
investigate the effect of miR-148a on the 
expression of PXR protein, 50 nM precursor or 
50 nM AsO for miR-148a or control were 
transfected into HepG2 cells using 
Lipofectamine RNAiMAX. After 72 h, total 
RNA was isolated using ISOGEN and the 
mature miR-148a levels were determined by 
Northern blotting as described above. Nuclear 
extract was isolated using the NE-PER Nuclear 
and Cytoplasmic extraction reagents (Pierce, 
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Rockford, IL) according to the manufacturer’s 
protocol. LS180 cells were transfected with 50 
nM precursor for miR-148a or control using 
Lipofectamine RNAiMAX. After 72 h, the cells 
were treated with 50 µM rifampicin or 0.1% 
(v/v) DMSO for 24 h. Then, total RNA and 
nuclear extract were isolated.  
 
     Evaluation of the expression level of PXR in 
HepG2 using reporter construct containing PXR 
responsive element - The reporter construct 
pCYP3A4-362-7.7K contains the promoter 
region (-362 to +11) including the ER6 (everted 
repeat separated by six nucleotides) motif and 
the distal enhancer region (-7836 to -7200) 
including the DR3 (direct repeat separated by 
three nucleotides) motif of the CYP3A4 gene, to 
which PXR binds (21). The day before 
transfection, HepG2 cells were seeded into 
24-well plates. After 24 h, 180 ng of 
pCYP3A4-362-7.7K, 20 ng of pGL4.74-TK 
plasmid and various doses of the precursors and 
AsOs for miR-148a or control were transfected 
using Tfx-20 reagent. After incubation for 48 h, 
the cells were treated with 10 µM rifampicin or 
0.1% DMSO for 24 h, and then the luciferase 
activity was measured.  
 
     Statistical analyses - Statistical significance 
was determined by analysis of variance followed 
by Dunnett multiple comparisons test or Tukey 
method test. Comparison of two groups was 
made with an unpaired, two-tailed student's t test. 
Correlation analyses were performed by 
Spearman rank method. A value of P < 0.05 was 





     PXR protein level is not associated with PXR 
mRNA level in human livers - We first examined 
the PXR mRNA level in a panel of 25 human 
livers by real-time RT-PCR assay and 
investigated the relationship with the PXR 
protein level. As shown in Fig. 1, no statistically 
significant correlation was observed between the 
PXR mRNA and protein levels (Rs = 0.10), 
indicating the involvement of 
post-transcriptional regulation of human PXR. 
To uncover the molecular mechanism of the 
post-transcriptional regulation, we sought to 
examine the involvement of miRNA-mediated 
regulation. Employing an on-line search using 
the miRBase Target database (15, 
http://microrna.sanger.ac.uk/), potential 
recognition elements for 16 kinds of miRNA 
such as miR-148a, miR-192, miR-560 were 
found in the 3’ UTR in human PXR. Among 
them, we focused on miR-148a because it is 
selectively and abundantly expressed in liver 
(22) and has high complementarity in the 5’ end 
at miRNA-mRNA duplexes including the seed 
sequence. The potential miR-148a target site is 
approximately 200 bases downstream of the stop 
codon of the human PXR mRNA. The alignment 
of hsa-miR-148a with the 3’ UTR of human 
PXR mRNA (Fig. 2A) was drawn using 
RNAhybrid (23, 
http://bibiserv.techfak.uni-bielefeld.de/rnahybrid
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/). We investigated whether this region termed 
the miR-148a recognition element 
(PXRMRE148) might be involved in the 
regulation of PXR by miR-148a. 
 
     Expression levels of miR-148a in human 
cancer cell lines – Real-time RT-PCR analysis 
using NCode miRNA First-Strand cDNA 
Synthesis Kit was performed to determine the 
expression levels of mature miR-148a in 8 kinds 
of human cancer cell lines (Fig. 2B). The mature 
miR-148a was detected in all cell lines tested in 
this study, with large variability among cell lines 
(37-fold). The U6 snRNA levels, which were 
used for normalization, varied 3-fold much less 
than the miR-148a levels in these cell lines. The 
mature miR-148a was higher in HepG2 and 
differentiated Caco-2 cells than the other cell 
lines. It was also interesting that, in Caco-2 cells, 
the expression level of mature miR-148a was 
increased with differentiation. Thus, the 
expression levels of mature miR-148a were 
highly variable among the human cancer cell 
lines.  
 
     Repressive regulation of PXR by miR-148a in 
human cell lines - To investigate whether 
PXRMRE148 is functional in the regulation by 
miR-148a, luciferase assays were performed 
with HEK293 cells (Fig. 2C). We first confirmed 
that the luciferase activity of the pGL3p/c-148a 
plasmid, in which the miR-148a complementary 
sequence was inserted downstream of the 
luciferase gene, was significantly (P < 0.01) 
decreased by the co-transfection with the 
precursor for miR-148a. The luciferase activity 
of pGL3p/3xPXRMRE plasmid, in which three 
copies of the potential miR-148a recognition site 
were inserted downstream of the luciferase gene, 
was also significantly (P < 0.01) decreased by 
co-transfection with the precursor for miR-148a 
(33% of control), while that of 
pGL3p/3xPXRMRE-Rev plasmid with the 
inverted recognition site was not affected. In 
HepG2 cells, which showed the highest 
expression of miR-148a (Fig. 2B), the luciferase 
activities of pGL3p/c-148a and 
pGL3p/3xPXRMRE plasmid were significantly 
(P < 0.01) lower than those of the control pGL3p 
plasmid (Fig. 2D). These activities were 
significantly (P < 0.01) restored by the 
transfection of AsO for miR-148a. In contrast, 
although the miR-148a recognition site was also 
present in the 3’ UTR of CYP3A4 mRNA, 
luciferase assay revealed that it was not affected 
by overexpression or inhibition of miR-148a 
(Supplemental figure 1). These results 
underscore that miR-148a functionally 
recognizes PXRMRE148 to decrease the 
expression. 
 
     Effects of overexpression or inhibition of 
miR-148a on the PXR protein level in a human 
cell line - We next examined the change in 
endogenous PXR protein expression by the 
overexpression or inhibition of miR-148a. By the 
transfection of the precursor for miR-148a into 
HepG2 cells that harbor the increased level of 
mature miR-148a, the PXR protein level was 
significantly (P < 0.05) decreased compared 
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with the control (Fig. 3A). Conversely, by the 
transfection of the AsO for miR-148a into 
HepG2 cells, where the expression of mature 
miR-148a was extinguished, the PXR protein 
level was significantly (P < 0.05) increased 
compared with the control (Fig. 3B). Meanwhile, 
the expression level of RXRα protein, a 
heterodimer partner of PXR, was not affected by 
the overexpression or inhibition of miR-148a. It 
is well known that ligand-activated PXR 
activates the transcription of targets by binding 
to the responsive element. Using the 
pCYP3A4-362-7.7K plasmid containing the 
PXR responsive element as a reporter construct, 
the changes in the PXR protein levels were 
monitored with the reporter activity (Fig. 3C and 
3D). The luciferase activity of 
pCYP3A4-362-7.7K plasmid was prominently 
(5.3-fold) increased by the treatment with 
rifampicin in HepG2 cells (Fig. 3E). 
Transfection of the precursor for miR-148a 
significantly decreased both the 
rifampicin-induced and basal transcriptional 
activities, resulting in a dose-dependent decrease 
of the induction. In contrast, the transfection of 
antisense for miR-148a significantly increased 
both the rifampicin-induced and basal 
transcriptional activity, resulting in a 
dose-dependent increase of the induction (Fig. 
3F). These results suggest that miR-148a 
negatively regulates the expression of PXR 
protein and, subsequently, the induction of its 
targets. 
 
     Role of miR-148a-dependent PXR regulation 
in the induction of endogenous CYP3A4 mRNA in 
a human cell line - We next sought to examine 
whether the miR-148a-dependent change of the 
PXR protein level affects the CYP3A4 induction 
in human cells. LS-180 cells were used because 
this cell line expressed relatively higher 
CYP3A4 mRNA than the other cell lines (data 
not shown). By the transfection of the precursor 
for miR-148a into the LS-180 cells, the PXR 
protein level was significantly (P < 0.01) 
decreased (Fig. 4A), concomitant with dramatic 
increase of the mature miR-148a level, while the 
PXR mRNA level was not decreased at any time 
after the transfection (Fig. 4B). The RXRα 
protein level was not affected by the 
overexpression of miR-148a (Fig. 4A). As shown 
in Fig. 4C, the CYP3A4 mRNA level was 
significantly increased by the treatment with 
rifampicin (5.0-fold). However, this induction 
was decreased by the overexpression of 
miR-148a, although the basal CYP3A4 mRNA 
level was not affected. These results suggest that 
the miR-148a-dependent regulation of PXR 
affects the induction of CYP3A4. 
 
     The miR-148a-dependent PXR regulation may 
control CYP3A4 expression in human liver tissue 
- To further investigate the effects of the 
miR-148a-dependent regulation of PXR in 
human liver tissue, the relationships between the 
expression levels of miR-148a, PXR, and 
CYP3A4 were investigated using a panel of 25 
human livers (Supplemental Table 1). The 
expression levels of miR-148a were variable 
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(95-fold) in the panel of human livers. The 
miR-148a level in liver sample No. 18 was 
comparable to that in HepG2 cells. The PXR 
mRNA (75-fold) and CYP3A4 mRNA 
(363-fold) were also variable. As shown in Fig. 1, 
the PXR mRNA level was not correlated with 
the PXR protein level. In contrast, the CYP3A4 
mRNA level was significantly correlated (Rs = 
0.67, P < 0.001) with the CYP3A4 protein level 
(Fig. 5A). When the PXR protein/PXR mRNA 
ratios were calculated as an index of the 
translational efficiency of PXR, they were 
inversely correlated with the miR-148a level (Rs 
= -0.41, P < 0.05, Fig. 5B), suggesting that PXR 
is negatively regulated by miR-148a in human 
liver. The PXR protein level was significantly 
correlated with both the CYP3A4 mRNA level 
(Rs = 0.47, P < 0.05, Fig. 5C) and the CYP3A4 
protein level (Rs = 0.67, P < 0.001, Fig. 5D). As 
summarized in Fig. 5E, the post-transcriptional 
regulation of PXR by miR-148a appeared to 






     PXR regulates at least 40 genes encoding 
proteins responsible for the metabolism and 
elimination of drugs (14). The study of PXR 
regulation assists in the understanding of the 
inter- and intra-individual variability in the 
pharmacokinetics of drugs. Although many 
research groups have found variability in the 
PXR mRNA levels in human liver samples, the 
correlation with its protein level has not fully 
been investigated. In this study, we first 
demonstrated that there was no significant 
correlation between them in human livers. For 
human PXR, two splicing variants, including 
exon 1b (PXR.2) or deleting the 5’-end of the 
exon 5 (PXR.3), have been reported (24, 25), 
which cannot be distinguished with our PCR 
primers. However, since the expression levels of 
these splicing variants were extremely low in our 
analysis (data not shown), consistent with a 
report by Lamba et al. (26), the dissociation of 
the PXR protein level with its mRNA level is not 
an artificial phenomenon. Identification of the 
miRNA recognition element in the human PXR 
gene suggested the involvement of miRNA in 
the regulation of PXR. 
          The luciferase assays showed that the 
endogenous and exogenous miR-148a negatively 
regulated the activity through PXRMRE148. In 
addition, the endogenous PXR protein level was 
diminished by the overexpression of miR-148a 
and elevated by its inhibition. These results 
clearly indicated that human PXR is 
post-transcriptionally regulated by miR-148a. 
The miR-148a-dependent changes of PXR 
protein affected the induction of CYP3A4 in 
LS180 cells. To further investigate whether the 
miR-148a affects the induction of other targets 
of PXR, we determined the expression levels of 
MDR1 and CYP2B6 in LS180 cells (data not 
shown). Rifampicin induced the MDR1 (5-fold) 
and CYP2B6 (2-fold) mRNAs, known targets of 
PXR (27, 28), and the induction was attenuated 
by the overexpression of miR-148a. Thus, the 
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miR-148a-dependent regulation of PXR 
appeared to affect its target genes in common. 
     Interestingly, the miR-148a recognition 
element is also present in the 3’-UTR of 
CYP3A4 mRNA. The complementarity of 
CYP3A4 with miR-148 (score 15.48, energy 
-24.27) was higher than that of human PXR 
(score 15.14, energy -19.52). To investigate 
whether CYP3A4 is directly regulated by 
miR-148a, luciferase assays were performed 
using a plasmid containing three copies of the 
miR-148a recognition element in the CYP3A4 
gene. However, unlike the PXRMRE, the 
element in CYP3A4 did not respond to 
miR-148a (Supplemental figure 1), indicating 
that CYP3A4 is not directly regulated by 
miR-148a.  
     In the panel of human livers, the expression 
level of miR-148a was inversely correlated with 
the translational efficiency of PXR, supporting 
the role of miR-148a in the regulation of PXR in 
liver. The significant correlation between the 
CYP3A4 mRNA and the CYP3A4 protein level 
in human livers in this study, in accordance with 
previous studies (29, 30), supported the finding 
that miRNA did not directly regulate the 
CYP3A4 expression. The PXR protein level was 
correlated with the CYP3A4 mRNA level in 
human liver, indicating that miR-148a affects the 
CYP3A4 expression through modulating PXR 
expression. The PXR protein level was not 
correlated with the CYP2B6 (Rs = 0.31, P > 0.1) 
or MDR1 (Rs = -0.20, P > 0.3) mRNA levels in 
the panel of human livers (data not shown), in 
contrast to CYP3A4. Thus, we speculate that the 
PXR does not largely affect the constitutive 
expression of CYP2B6 and MDR1 in liver. In 
our panel of human livers, the CYP3A4 mRNA 
level was not correlated with the HNF4α protein 
level (Rs = -0.14, P > 0.5) or CAR protein level 
(Rs = 0.12, P > 0.5), indicating a significant 
contribution of PXR to the constitutive CYP3A4 
level.  
     Most of the genes in the vertebrate nuclear 
receptor superfamily are strongly conserved 
between species. The ligand-binding domain of 
PXR shares amino acid identity of 75% between 
human and rodent, which can explain why the 
key ligands for PXR vary across species. 
Meanwhile, the DNA-binding domain of PXR 
shares more than 95% amino acid identity (1) 
inducing a similar set of genes. Most miRNAs 
are evolutionally conserved, which suggests that 
the miRNA-mediated regulation of certain genes 
would be common among species. The MRE148 
is also identified in the 3’ UTR in mouse PXR 
(score 16.63, energy -21.4) and rat PXR (score 
and energy are not calculated at miRBase, but 
has only a 1-base difference with the 
corresponding mouse sequence) at ~670-bp 
downstream of the stop codon, although the 3’ 
UTR of PXR is poorly conserved between 
human and rodent. It is therefore possible that 
rodent PXR may also be regulated by miR-148a, 
suggesting that a rodent might be a useful model 
animal to investigate the role of miR-148a in 
drug metabolism and elimination in vivo. 
     In conclusion, we found that human PXR is 
post-transcriptionally regulated by miR-148a 
affecting the CYP3A4 level in human liver. This 
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study would provide new insight into the 
unsolved mechanism of the large interindividual 
variability of CYP3A4 expression.  
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FIGURE 1. Correlation between the PXR mRNA and protein levels in 25 human livers. The PXR 
mRNA level was determined by real-time RT-PCR and normalized with the GAPDH mRNA level. 
The PXR protein level was determined by western blot analysis and normalized with the GAPDH 
protein level.  
 
FIGURE 2. Repressive regulation of human PXR by miR-148a. A, Complementarity of miR-148a 
to the predicted target sequence of human PXR. The potential miR-148a recognition element 
(PXRMRE148) is located on +3359 to +3386 in the 3’ UTR of human PXR mRNA, where the 
numbering refers to the 5’ end of mRNA as 1. B, The mature miR-148a levels in HepG2, HuH7, HLE, 
Caco-2, Caco-2/D (differentiated), LS180, HEK293, MCF-7 cells were determined by real-time 
RT-PCR analysis using NCode miRNA First-Strand cDNA Synthesis Kit. The values were the mature 
miR-148a levels normalized with the U6 snRNA levels relative to that in HLE cells. C, D, Luciferase 
assays were performed to investigate whether PXRMRE148 is functional in the regulation by 
miR-148a. The reporter constructs were transiently transfected with 4 pmol of the precursors for 
miR-148a or control into HEK293 cells (C) or 10 pmol of the AsO for miR-148a or control into 
HepG2 cells (D). The data were the firefly luciferase activities normalized with the Renilla luciferase 
activities relative to that of pGL3p plasmid. Each column represents the mean ± SD of three 
independent experiments. **P < 0.01, compared with pGL3p; ††P < 0.01, †††P < 0.001, compared 
with AsO for control. 
 
FIGURE 3. Effects of overexpression or inhibition of miR-148a on the PXR protein level in 
HepG2 cells. The precursors for miR-148a or control (50 nM, A) or AsOs for miR-148a or control 
(50 nM, B) were transfected into HepG2 cells. After 72 h, the cells were harvested and total RNA and 
nuclear extracts were isolated. A, B, The mature miR-148a levels were determined by real-time 
RT-PCR analyses. The values were the mature miR-148a levels normalized with the U6 snRNA 
levels relative to control. The PXR and RXRα protein levels in nuclear extracts were determined by 
western blot analyses. The values are the mean ± SD for three independent experiments (*P < 0.05, 
compared with control). C, D, Schemes represent the principle of the reporter gene assay to evaluate 
the changes in the endogenous PXR protein level by the overexpression (C) or inhibition (D) of 
miR-148a. The pCYP3A4-362-7.7K plasmid contains the PXR responsive elements, ER6 (-362 to 
+11) and DR3 (-7836 to -7200), of the CYP3A4 gene upstream of the luciferase gene. E, F, The cells 
were transfected with the reporter plasmid and the precursors or AsOs. After 48 h, the cells were 
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treated with 10 µM rifampicin (square symbols) or 0.1% DMSO (circle symbols) for 24 h. The data 
were the firefly luciferase activities normalized with the Renilla luciferase activities relative to that of 
pGL3p plasmid without the precursors or AsOs. Each point represents the mean ± SD of three 
independent experiments. *P < 0.05, **P < 0.01, ***P < 0.001, compared with control.  
 
FIGURE 4. Effects of overexpression of miR-148a on the induction of endogenous CYP3A4 
mRNA in LS180 cells. A, B, The precursors for miR-148a or control (50 nM) were transfected into 
LS180 cells. A, After 72 h, the cells were harvested and total RNA and nuclear extracts were isolated. 
The mature miR-148a level was determined by real-time RT-PCR analysis. The values are the mature 
miR-148a levels normalized with the U6 snRNA levels relative to control. The PXR and RXRα 
protein levels were determined by western blot analysis. The values are the mean ± SD of three 
independent experiments (**P < 0.01, compared with control). B, After 24, 48, 72, 96 hr, the cells 
were harvested and total RNA was isolated. The PXR mRNA level was determined by real-time 
RT-PCR analysis. The values are the PXR mRNA levels normalized with the GAPDH mRNA levels 
relative to control. Each point represents the mean ± SD of three independent experiments. C, 
Precursor-transfected LS180 cells were treated with 50 µM rifampicin or 0.1% DMSO for 24 h and 
then total RNA was isolated. The CYP3A4 mRNA levels were determined by real-time RT-PCR and 
normalized with the GAPDH mRNA level. The data are relative to that with the precursor for the 
control without rifampicin. Each column represents the mean ± SD of three independent experiments. 
***P < 0.001; NS: Not significant.  
 
FIGURE 5. Relationship between the expression levels of miR-148a, PXR, and CYP3A4 in 
human liver tissue. A, The CYP3A4 mRNA level was significantly correlated with the CYP3A4 
protein levels. B, The miR-148a level was inversely correlated with the translational efficiency of 
PXR (PXR protein/mRNA ratio). C, D, The PXR protein level was significantly correlated with the 
CYP3A4 mRNA (C) and protein level (D). E, Summary of the correlation analyses (*P < 0.05, **P < 
0.01, ***P < 0.001). 
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